Skip To Main Content
Kenneth J O'Byrne on Muck Rack

Kenneth J O'Byrne

As seen in: Wiley Online Library, Business Wire, Frontiers, BioRxiv, Morningstar, The Lancet, Cell Reports Medicine, ADVFN, Stockhouse, MarketScreener and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Kenneth J

Contact Kenneth J, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature

|
By Richard Lobb, Quan Zhou, David Fielding, Kekoolani S. Visan, Alain Wuethrich, Jing Wang, Emma Norris, Sarah Everitt, Lauren G. Aoude, Vanessa F. Bonazzi, Elizabeth Nixon, Jennifer Mooi, Kevin Koo, Kenneth J O'Byrne, Arutha Kulasinghe, Rayleen V Bowman, Ian A Yang, Niall M. Corcoran, Christopher M. Hovens, Michael M MacManus, Jeffrey Gorman, Gunter Hartel, David Whiteman, Niall C Tebbutt, John M. Mariadason, Kwun M. Fong, Andrew Barbour, Matt Trau, Andreas Möller, Youran Hu, Marcus L. Hastie, Brielle Parris
| Cell Reports Medicine Verified
ArticleOnline now102694Open access Affiliations & Notes 1Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, QLD 4072, Australia 2Tumour Microenvironment Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, QLD 4006, Australia 3Department of Thoracic Medicine, Royal Brisbane and Women’s Hospital, Brisbane, QLD 4029, Australia 4JC STEM Lab, Department of Otorhinolaryngology, Chinese University of Hong Kong, Shatin, Hong Kong...
Open in Who Shared Issue with article?

Katsuaki Maehara: TTF-1 is a New Marker to Identify Patients Best Suited for Lung Cancer KRAS Inhibitors  - OncoDaily

|
By Kenneth J O'Byrne
| OncoDaily
Katsuaki Maehara, Director of Medical Education Colleagues, shared a post on X about a recent paper shared by Ferdinandos Skoulidis et al. published in Nature: “TTF-1 is a new marker to identify patients best suited for lung cancer KRAS inhibitors Sotorasib – KRAS G12C mut Lung cancer patients with high TTF-1 expression had improved survival outcomes after treatment with the KRAS inhibitor Sotrasib.
Open in Who Shared Issue with article?

Jay Bradner: Molecular Determinants of Sotorasib Clinical Efficacy in KRASG12C-NSCLC

|
By Kenneth J O'Byrne
| OncoDaily
Jay Bradner, Executive Vice President of R&D, and Chief Scientific Officer at Amgen, posted on X: “A new Nature Medicine study sheds light on why KRAS G12C–mutated NSCLC patients respond differently to treatment. Insights from two trials reveal molecular features and early blood-based markers that may predict outcomes.
Open in Who Shared Issue with article?
See all 35 articles